Invention Grant
- Patent Title: Immunogenic treatment of cancer
-
Application No.: US16225028Application Date: 2018-12-19
-
Publication No.: US11318193B2Publication Date: 2022-05-03
- Inventor: Charles Akle , Satvinder Mudan , John Grange
- Applicant: Immodulon Therapeutics Limited
- Applicant Address: GB London
- Assignee: Immodulon Therapeutics Limited
- Current Assignee: Immodulon Therapeutics Limited
- Current Assignee Address: GB London
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: GB1120779 20111202
- Main IPC: A61K39/04
- IPC: A61K39/04 ; A61K39/00 ; A61K35/74 ; A61N5/10 ; A61K45/06

Abstract:
The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.
Public/Granted literature
- US20190224294A1 Immunogenic Treatment Of Cancer Public/Granted day:2019-07-25
Information query